This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Illumina (ILMN)

Tipranks - Tipranks - Fri Jul 24, 5:26AM CDT

Analysts fell to the sidelines weighing in on Merck & Company (MRK) and Illumina (ILMN) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Claim 55% Off TipRanks

Merck & Company (MRK)

Bernstein analyst Courtney Breen maintained a Hold rating on Merck & Company yesterday and set a price target of $100.00. The company’s shares closed last Wednesday at $127.47, close to its 52-week high of $134.63.

According to TipRanks.com, Breen is a 4-star analyst with an average return of 18.6% and a 84.9% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Eli Lilly & Co. ;'>

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $136.35, representing a 7.1% upside. In a report issued on July 9, Morgan Stanley also maintained a Hold rating on the stock with a $113.00 price target.

See the top stocks recommended by analysts >>

Illumina (ILMN)

In a report released yesterday, Eve Burstein from Bernstein maintained a Hold rating on Illumina, with a price target of $185.00. The company’s shares closed last Wednesday at $190.87.

According to TipRanks.com, Burstein is a 4-star analyst with an average return of 26.9% and a 70.0% success rate. Burstein covers the Healthcare sector, focusing on stocks such as Guardant Health, Thermo Fisher, and Agilent. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Illumina with a $171.13 average price target, implying a -9.9% downside from current levels. In a report issued on July 15, TD Cowen also maintained a Hold rating on the stock with a $192.00 price target.

Read More on MRK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).